Results 21 to 30 of about 11,024,988 (313)

Haploidentical CD19/CD22 bispecific CAR-T cells induced MRD-negative remission in a patient with relapsed and refractory adult B-ALL after haploidentical hematopoietic stem cell transplantation

Journal of Hematology & Oncology, 2019
Background Chimeric antigen receptor T (CAR-T) cell therapy simultaneously against CD19 and CD22 is an attractive strategy to address the antigen escape relapse after CD19-directed CAR-T cell therapies. However, the potential of optimizing the durability
Hejin Jia, Zhenguang Wang, Yao Wang, Yang Liu, Hanren Dai, Chuan Tong, Yelei Guo, Bo Guo, Dongdong Ti, Xiao Han, Qingming Yang, Zhiqiang Wu, Weidong Han   +12 more
doaj   +1 more source

CAR-T Therapy in Oncology Nursing

, 2021
CAR-T nursing training is ...
Xiao Xue Zeng (11692221)
core   +1 more source

Novel allogeneic CAR T-cell platform involving microhomology-mediated end joining repair and low off-targeting potential

Molecular Therapy: Nucleic Acids
Several allogeneic chimeric antigen receptor (CAR) T-cell therapies in clinical trials rely on CRISPR-Cas genome editing, but the enzyme’s random repair mechanism increases the risk of undesired off-target effects, challenging safe CAR T-cell generation.
Tanya Hundal, Yan Luo, Yaqing Qie, Martha E. Gadd, Andrew D. Brim, Isas Vazquez-Rosario, Shaohua Guo, Mohamed A. Kharfan-Dabaja, Hong Qin   +8 more
doaj   +1 more source

CAR Talk: How Cancer-Specific CAR T Cells Can Instruct How to Build CAR T Cells to Cure HIV

Frontiers in Immunology, 2019
Re-directing T cells via chimeric antigen receptors (CARs) was first tested in HIV-infected individuals with limited success, but these pioneering studies laid the groundwork for the clinically successful CD19 CARs that were recently FDA approved.
Gloria B. Kim, Kristen Hege, James L. Riley   +2 more
doaj   +1 more source

IL-7 and CCR2b Co-Expression-Mediated Enhanced CAR-T Survival and Infiltration in Solid Tumors

Frontiers in Oncology, 2021
Chimeric antigen receptor T (CAR-T) cells are not effective in solid tumor treatment due to reduced invasion and expansion, and short survival time. This study aimed to explore whether interleukin (IL)-7 and CCR2b expression could improve GD2-CAR-T cell ...
Guangchao Li, Guangchao Li, Qing Zhang, Zeping Han, Yangmin Zhu, Huijuan Shen, Zhi Liu, Zhao Zhou, Wen Ding, Siqi Han, Jinhua He, Zhao Yin, Jie Zhou, Ruiming Ou, Min Luo, Min Luo, Shuang Liu   +16 more
doaj   +1 more source

Protocol for engineering binding domains to recognize ligand-bound receptors by using yeast surface display

STAR Protocols
Summary: Yeast surface display is a versatile protein engineering technology, enabling precise control of the applied selection pressure. We present a yeast-surface-display-based protocol for the enrichment of binders specifically recognizing ligand ...
Markus Dobersberger, Delia Sumesgutner, Charlotte U. Zajc, Michael W. Traxlmayr   +3 more
doaj   +1 more source

Monitoring of Circulating CAR T Cells: Validation of a Flow Cytometric Assay, Cellular Kinetics, and Phenotype Analysis Following Tisagenlecleucel

Frontiers in Immunology, 2022
Chimeric antigen receptor (CAR) T cell therapy is a potent new treatment option for relapsed or refractory hematologic malignancies. As the monitoring of CAR T cell kinetics can provide insights into the activity of the therapy, appropriate CAR T cell ...
Andreas Peinelt, Andreas Peinelt, Melanie Bremm, Melanie Bremm, Hermann Kreyenberg, Hermann Kreyenberg, Claudia Cappel, Claudia Cappel, Julia Banisharif-Dehkordi, Julia Banisharif-Dehkordi, Stephanie Erben, Stephanie Erben, Eva Rettinger, Eva Rettinger, Andrea Jarisch, Andrea Jarisch, Roland Meisel, Paul-Gerhardt Schlegel, Olaf Beck, Gesine Bug, Jan-Henning Klusmann, Thomas Klingebiel, Sabine Huenecke, Sabine Huenecke, Peter Bader, Peter Bader   +25 more
doaj   +1 more source

5G connected and automated driving: use cases, technologies and trials in cross-border environments

EURASIP Journal on Wireless Communications and Networking, 2021
Cooperative, connected and automated mobility (CCAM) across Europe requires harmonized solutions to support cross-border seamless operation. The possibility of providing CCAM services across European countries has an enormous innovative business ...
Dirk Hetzer, Maciej Muehleisen, Apostolos Kousaridas, Sokratis Barmpounakis, Stefan Wendt, Kurt Eckert, Andreas Schimpe, Johan Löfhede, Jesus Alonso-Zarate   +8 more
doaj   +1 more source

Engineered TAP1 and TAP2 Proteins to Block the CD7 and HLA-I Surface Expression on CAR-T Cells

, 2022
reservedChimeric antigen receptor (CAR) T-cells are a novel and powerful cancer treatment, particularly for hematologic malignancies like lymphomas or leukemias.
BRUNELLO, VALERIA
core  

CAR T sejtek ioncsatornáinak funkcionális vizsgálata

, 2021
A T-sejtek specifikus antigén felismerése a TCR/CD3 receptor komplex és az antigén prezentáló sejtek MHC molekulái között létrejövő kölcsönhatás eredménye, melyet klonális proliferáció, differenciálódás követ, ezzel biztosítva az immunrendszer ...
Jusztus, Vivien
core